Anti-influenza serum and mucosal antibody responses after administration of live attenuated or inactivated influenza vaccines to HIV-infected children

Journal of Acquired Immune Deficiency Syndromes

Volumn 55, Issue 2, 2010, Pages 189-196

  Weinberg, Adriana ^a   Song, Lin Ye ^b   Walker, Robert ^c   Allende, Maria ^c   Fenton, Terence ^a   Patterson Bartlett, Julie ^b   Nachman, Sharon ^d   Kemble, George ^c   Yi, Ting Ting ^c   Defechereux, Patricia ^e   Wara, Diane ^e   Read, Jennifer S ^f   Levin, Myron ^a  

^a Children's Hospital Colorado   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c MEDIMMUNE   (United States)

^d STONY BROOK UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Antibodies; HIV infected children; Influenza vaccines; Viral shedding

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; LIVE VACCINE; VIRUS ANTIBODY; INACTIVATED VACCINE; NEUTRALIZING ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD; CHILD; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZATION; SALIVA; SCHOOL CHILD; VIRUS LOAD; VIRUS SHEDDING; CONTROLLED STUDY; IMMUNOLOGY; MUCOSAL IMMUNITY; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; IMMUNITY, MUCOSAL; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; MALE; SALIVA; VACCINES, ATTENUATED; VACCINES, INACTIVATED; VIRUS SHEDDING;

EID: 77957317986     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181e46308     Document Type: Article

References (29)

1. Fiore AE, Shay DK, Broder K, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep. 2009; 58(RR-8):1-52.
2. Yamanaka H, Teruya K, Tanaka M, et al. Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2005;39:167-173.
3. Atashili J, Kalilani L, Adimora AA. Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: A meta-analysis. BMC Infect Dis. 2006;6:138.
4. Amendola A, Boschini A, Colzani D, et al. Influenza vaccination of HIV-1-positive and HIV-1-negative former intravenous drug users. J Med Virol. 2001;65:644-648.
5. Iorio AM, Alatri A, Francisci D, et al. Immunogenicity of influenza vaccine (1993-94 winter season) in HIV-seropositive and -seronegative ex-intravenous drug users. Vaccine. 1997;15:97-102.
6. Kroon FP, van Dissel JT, de Jong JC, et al. Antibody response after influenza vaccination in HIV-infected individuals: A consecutive 3-year study. Vaccine. 2000;18:3040-3049.
7. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med. 1998;338:1405-1412.
8. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007;356:685-696.
9. Ashkenazi S, Vertruyen A, Aristegui J, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J. 2006;25:870-879.
10. Fleming DM, Crovari P, Wahn U, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J. 2006;25:860-869.
11. Belshe RB, Gruber WC, Mendelman PM, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr. 2000;136:168-175.
12. Quan FS, Compans RW, Nguyen HH, et al. Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J Virol. 2008;82: 1350-1359.
13. Tam JS, Capeding MR, Lum LC, et al. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against cultureconfirmed influenza in young children in Asia. Pediatr Infect Dis J. 2007; 26:619-628.
14. Rhorer J, Ambrose CS, Dickinson S, et al. Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials. Vaccine. 2009;27:1101-1110.
15. Bracco Neto H, Farhat CK, Tregnaghi MW, et al. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children. Pediatr Infect Dis J. 2009;28:365-371.
16. Levin MJ, Song LY, Fenton T, et al. Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine. 2008;26:4210-4217.
17. Block SL, Yogev R, Hayden FG, et al. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Vaccine. 2008;26:4940-4946.
18. Treanor J, Wright PF. Immune correlates of protection against influenza in the human challenge model. Dev Biol (Basel). 2003;115:97-104.
19. Treanor JJ, Kotloff K, Betts RF, et al. Evaluation of trivalent, live, coldadapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine. 1999;18: 899-906.
20. Forrest BD, Pride MW, Dunning AJ, et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol. 2008;15:1042-1053.
21. Hammitt LL, Li S, Patterson-Bartlett J, et al. Kinetics of viral shedding and immune responses to cold-adapted influenza vaccine. Vaccine. 2009; 27:7359-7366.
22. Boyce TG, Gruber WC, Coleman-Dockery SD, et al. Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children. Vaccine. 1999;18:82-88.
23. Gorse GJ, Otto EE, Powers DC, et al. Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly. J Infect Dis. 1996;173:285-290.
24. Tomoda T, Morita H, Kurashige T, et al. Prevention of influenza by the intranasal administration of cold-recombinant, live-attenuated influenza virus vaccine: importance of interferon-gamma production and local IgA response. Vaccine. 1995;13:185-190.
25. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull. 1979;35:69-75.
26. Ohmit SE, Victor JC, Rotthoff JR, et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med. 2006; 355:2513-2522.
27. Monto AS, Ohmit SE, Petrie JG, et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med. 2009;361: 1260-1267.
28. Edwards KM, Dupont WD, Westrich MK, et al. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis. 1994;169:68-76.
29. Piedra PA, Glezen PW. Influenza in children: epidemiology, immunity and vaccines. Semin Pediatr Infect Dis. 1991;2:140-146.